VCRE offering history
Every offering-related filing in Vicore Pharma Holding AB’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 6 filings back to Apr 17, 2026.
No offering-related filings (registrations, 424B pricing supplements, 8-K item 3.02 sales) in the 6 filings EDGAR returns for Vicore Pharma Holding AB, reviewed back to Apr 17, 2026. That is the reviewed window, not a claim about earlier years.
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
VCRE offering FAQ
When did VCRE last execute an offering?
No executed-offering document (424B pricing supplement or 8-K item 3.02) appears in the 6 filings EDGAR returns for Vicore Pharma Holding AB, reviewed back to 2026-04-17.
When did VCRE last announce or register an offering?
No offering registration (S-1/S-3/F-1/F-3) appears in the filings reviewed back to 2026-04-17.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.